← Back to Search

Unknown

ANK-700 for Multiple Sclerosis (MoveS-it Trial)

Phase 1
Waitlist Available
Research Sponsored by Anokion SA
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosed with RRMS per revised McDonald criteria (2017) with an EDSS score ≤ 6.5 at screening
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year
Awards & highlights

MoveS-it Trial Summary

This trial is testing a new drug, ANK-700, for multiple sclerosis. In part A, patients receive one dose of the drug to see if it is safe. In part B, patients will receive three doses of the drug or a placebo to see if it is effective.

Who is the study for?
This trial is for adults with relapsing remitting multiple sclerosis (RRMS) who are neurologically stable, not pregnant or breastfeeding, and either not on MS therapy or using fumarate drugs. They must be able to use effective birth control if applicable and have an EDSS score ≤ 6.5.Check my eligibility
What is being tested?
The study tests ANK-700's safety in RRMS patients. It has two parts: Part A gives a single dose of ANK-700; Part B involves three doses of either ANK-700 or a placebo to compare effects.See study design
What are the potential side effects?
Specific side effects aren't listed, but as this is a safety study for ANK-700, participants will be monitored for any adverse reactions which could range from mild symptoms like headaches to more serious ones depending on individual responses.

MoveS-it Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have relapsing-remitting MS with limited disability.

MoveS-it Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence and severity of treatment-emergent adverse events (TEAEs) as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0 or higher
Secondary outcome measures
Area under the plasma concentration-time curve from time 0 to the last measurable time point (AUC last)
Geometric mean of maximum plasma concentration (Cmax)

MoveS-it Trial Design

5Treatment groups
Experimental Treatment
Group I: MAD Cohort 5 ANK-700 Dose B or placeboExperimental Treatment2 Interventions
All enrolled patients will receive three doses of ANK-700 Dose B or placebo
Group II: MAD Cohort 4 ANK-700 Dose A or PlaceboExperimental Treatment2 Interventions
All enrolled patients will receive three doses of ANK-700 Dose A or placebo
Group III: ANK-700 SAD Cohort 3 Dose CExperimental Treatment1 Intervention
All enrolled patients will receive one dose of ANK-700 Dose C
Group IV: ANK-700 SAD Cohort 2, Dose BExperimental Treatment1 Intervention
All enrolled patients will receive one dose of ANK-700 Dose B
Group V: ANK-700 SAD Cohort 1, Dose AExperimental Treatment1 Intervention
All enrolled patients will receive one dose of ANK-700 Dose A
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670

Find a Location

Who is running the clinical trial?

Anokion SALead Sponsor

Media Library

ANK-700 (Unknown) Clinical Trial Eligibility Overview. Trial Name: NCT04602390 — Phase 1
Multiple Sclerosis Research Study Groups: ANK-700 SAD Cohort 1, Dose A, ANK-700 SAD Cohort 3 Dose C, MAD Cohort 4 ANK-700 Dose A or Placebo, MAD Cohort 5 ANK-700 Dose B or placebo, ANK-700 SAD Cohort 2, Dose B
Multiple Sclerosis Clinical Trial 2023: ANK-700 Highlights & Side Effects. Trial Name: NCT04602390 — Phase 1
ANK-700 (Unknown) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04602390 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any available slots for participants in this investigation?

"Affirmative. Online records from clinicaltrials.gov demonstrate that this research study, which was initially published on 6th November 2020, is still recruiting participants. About 33 individuals must be sourced across 11 sites."

Answered by AI

What evidence is there regarding the safety of ANK-700 for patients?

"There is minimal clinical data regarding the safety of ANK-700, so it earned a score of 1."

Answered by AI

Is it possible for me to register in the current experiment?

"This medical trial is looking to enrol 33 individuals diagnosed with relapsing remitting multiple sclerosis (RRMS) between the age of 18 and 60. To meet eligibility, participants must have experienced no neurological relapse within the preceding four weeks, possess an Expanded Disability Status Scale score under 6.5, not be taking any disease modifying medication or fumarate drugs like dimethyl fumarate/diroximel fumarate if already on a therapy regimen for MS, use effective contraception methods or confirm post-menopausal status with their Investigator and sign off on the Informed Consent Form (ICF)."

Answered by AI

Can you identify the hospitals participating in this experiment within city?

"This clinical study is enrolling participants at multiple locations, including Collier Neurologic in Naples, Florida, MS Center of Greater Washington in Vienna, Virginia and Ochsner Clinic Foundation in New Orleans, Louisiana. Additionally 11 other medical centres are also involved."

Answered by AI

How many participants are engaged in the current clinical research?

"The sponsor Anokion SA will be managing the trial across multiple sites, such as Collier Neurologic in Naples, Florida and MS Center of Greater Washington in Vienna, Virginia, with 33 eligible participants needed to fulfill the study's criteria."

Answered by AI

Does this research include participants of a venerable age?

"The entry criteria for this medical trial indicates that potential participants must be between 18 and 60 years old. Additionally, there are 43 trials specifically tailored to minors and 391 clinical studies suitable for those aged 65 or above."

Answered by AI

Who else is applying?

What state do they live in?
Mississippi
Texas
How old are they?
18 - 65
What site did they apply to?
University of Texas Health Science Center
Ochsner Clinic Foundation
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis
2020. "Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04602390.
All > Autoimmune Hemolytic Anemia > Multiple Sclerosis
~1 spots leftby Jun 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top